Brooke C Matson1, Kelsey E Quinn1, Bruce A Lessey2, Steven L Young3, Kathleen M Caron4. 1. Department of Cell Biology and Physiology, University of North Carolina, Chapel Hill, North Carolina. 2. Obstetrics and Gynecology, Greenville Health System, Greenville, South Carolina. 3. Department of Cell Biology and Physiology, University of North Carolina, Chapel Hill, North Carolina; Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, North Carolina. 4. Department of Cell Biology and Physiology, University of North Carolina, Chapel Hill, North Carolina. Electronic address: kathleen_caron@med.unc.edu.
Abstract
OBJECTIVE: To test adrenomedullin (Adm, ADM) as a downstream target of signal transducer and activator of transcription 3 (STAT3) in endometrial cells and to test midregional proadrenomedullin (MR-proADM) as a biomarker of endometriosis. DESIGN: Cross-sectional analysis of Adm expression in eutopic endometrium and of MR-proADM in plasma from women with and without endometriosis; and prospective study of MR-proADM levels in women with endometriosis undergoing surgical resection of ectopic lesions. SETTING: Academic medical centers. PATIENT(S): Fifteen patients with endometriosis and 11 healthy control subjects who donated eutopic endometrial biopsies; and 28 patients with endometriosis and 19 healthy control subjects who donated plasma for MR-proADM analysis. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Adm mRNA levels according to quantitative real-time polymerase chain reaction after activation of STAT3 by interleukin-6 (IL-6) in Ishikawa cells; immunohistochemistry for ADM in eutopic endometrial biopsies from women with endometriosis compared with healthy donors; and MR-proADM levels measured by commercial immunoassay in plasma from healthy women and women with endometriosis who subsequently underwent surgical resection of ectopic lesions. RESULT(S): Activation of STAT3 by IL-6 up-regulated Adm mRNA expression in Ishikawa cells. ADM protein levels were elevated in the eutopic endometrium of women with endometriosis. MR-proADM concentrations were higher in women with endometriosis but were not correlated with disease stage, corrected by surgery, or predictive of fertility outcome. CONCLUSION(S): MR-proADM may be able to serve as a biomarker of endometriosis, but it is unknown whether elevated MR-proADM levels are secondary to the estrogenic and inflammatory properties of endometriosis or an inciting pathogenic factor.
OBJECTIVE: To test adrenomedullin (Adm, ADM) as a downstream target of signal transducer and activator of transcription 3 (STAT3) in endometrial cells and to test midregional proadrenomedullin (MR-proADM) as a biomarker of endometriosis. DESIGN: Cross-sectional analysis of Adm expression in eutopic endometrium and of MR-proADM in plasma from women with and without endometriosis; and prospective study of MR-proADM levels in women with endometriosis undergoing surgical resection of ectopic lesions. SETTING: Academic medical centers. PATIENT(S): Fifteen patients with endometriosis and 11 healthy control subjects who donated eutopic endometrial biopsies; and 28 patients with endometriosis and 19 healthy control subjects who donated plasma for MR-proADM analysis. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Adm mRNA levels according to quantitative real-time polymerase chain reaction after activation of STAT3 by interleukin-6 (IL-6) in Ishikawa cells; immunohistochemistry for ADM in eutopic endometrial biopsies from women with endometriosis compared with healthy donors; and MR-proADM levels measured by commercial immunoassay in plasma from healthy women and women with endometriosis who subsequently underwent surgical resection of ectopic lesions. RESULT(S): Activation of STAT3 by IL-6 up-regulated Adm mRNA expression in Ishikawa cells. ADM protein levels were elevated in the eutopic endometrium of women with endometriosis. MR-proADM concentrations were higher in women with endometriosis but were not correlated with disease stage, corrected by surgery, or predictive of fertility outcome. CONCLUSION(S): MR-proADM may be able to serve as a biomarker of endometriosis, but it is unknown whether elevated MR-proADM levels are secondary to the estrogenic and inflammatory properties of endometriosis or an inciting pathogenic factor.
Authors: Rob D Catalano; Martin H Johnson; Elizabeth A Campbell; D Stephen Charnock-Jones; Stephen K Smith; Andrew M Sharkey Journal: Proc Natl Acad Sci U S A Date: 2005-06-03 Impact factor: 11.205
Authors: Sandeep Pawar; Elina Starosvetsky; Grant D Orvis; Richard R Behringer; Indrani C Bagchi; Milan K Bagchi Journal: Mol Endocrinol Date: 2013-10-07
Authors: Jacqueline A Maybin; Sharon Battersby; Nikhil Hirani; Leonid L Nikitenko; Hilary O D Critchley; Henry N Jabbour Journal: Endocrinology Date: 2011-05-10 Impact factor: 4.736
Authors: Mirjam Christ-Crain; Nils G Morgenthaler; Joachim Struck; Stephan Harbarth; Andreas Bergmann; Beat Müller Journal: Crit Care Date: 2005-11-15 Impact factor: 9.097
Authors: Giovanni Grandi; Angela Toss; Laura Cortesi; Laura Botticelli; Annibale Volpe; Angelo Cagnacci Journal: Biomed Res Int Date: 2015-08-30 Impact factor: 3.411
Authors: Xia Wang; Cheuk-Lun Lee; Madhavi Vijayan; William S B Yeung; Ernest H Y Ng; Xiwen Wang; Wai-Sum O; Raymond H W Li; Yuanzhen Zhang; Philip C N Chiu Journal: Mucosal Immunol Date: 2020-03-13 Impact factor: 7.313